

FORM PTO-1449
(R v. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket N.

Serial N.

MBHB00-618-A

09/648,775

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)



Applicant:

Biaggioni et al.

Filing Date:

8/22/00

Group:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriated
AB	4,089,959	5/16/78	Diamond			
AB	4,120,947	10/17/98	Diamond			
AB	4,325,956	4/20/82	Kjellin et al.			
AB	4,593,095	6/3/86	Snyder et al.			
AB	4,696,932	9/29/87	Jacobson et al			
AB	4,804,664	2/14/89	Kjellin et al.			
AB	5,516,894	5/14/96	Reppert			
AB	5,641,784	6/24/97	Kufner-Muhl et al.			
AB	5,646,156	7/8/97	Jacobsen et al			
AB	5,670,498	9/23/97	Suzuki et al.			
AB	5,703,085	12/30/97	Suzuki et al.			
AB	5,776,960	7/7/98	Oppong et al.			
AB	5,780,481	7/14/98	Jacobson et al.			
AB	5,854,081	12/29/98	Linden et al.			
AB	5,877,180	3/2/99	Linden et al			

EXAMINER

DATE CONSIDERED

9/13/00

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include copy of this form with
next communication.

Atty. Docket N.

Serial N.

MBHB00-618-A

09/648,775

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

Applicant:

Biaggioni et al.

Filing Date:

8/22/00

Group:

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
NY	EP 0 386 683	9/9/90	EP				
NY	2,064,742	12/23/91	Canada				
NY	WO 95/11681	5/4/95	WIPO				
NY	GB 228733	11/1/95	GB				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.).

M		Katsushima, et al., "Structure-Activity Relationships of 8-Cycloalkyl-1,3-dipropylxanthines as Antagonists of Adenosine Receptors", <i>J. Med. Chem.</i> 33:1906-1910 (1990)
MD		Martinson, et al., "Potent Adenosine Receptor Antagonists that are Selective for the A ₁ Receptor Subtype", <i>Molecular Pharmacology</i> , 31:247-252 (1986)
MM		Jacobson et al., "1,3-Dialkylxanthine Derivatives Having High Potency as Antagonists at Human A _{2B} Adenosine Receptors", <i>Drug Development Research</i> , 47:45-53 (1999)
MD		Kleiner, "Reactions of Some 8-(3-Pyridyl)-6-thioxanthines with Methyl Iodide" 739-743 (1973).
M		Klotz, et al., "Comparative pharmacology of human adenosine receptors subtypes-characterization of stably transfected receptors in CHO cells", <i>Nauny-Schmideberg's Arch Pharmacol</i> , 357:1-9 (1998).
MM		Linden, et al., "Characterization of Human A _{2B} Adenosine Receptors: Radioligand Binding, Western Blotting and Coupling to G _q in Human Embryonic Kidney 293 Cells and HMC-1 Mast Cells", <i>Molecular Pharmacology</i> 56:705-713 (1999).
M		Kim et al., "Acyl-Hydrazide Derivatives of a Xanthine Carboxylic Congener (XCC) as Selective Antagonists at Human A _{2B} Adenosine Receptors", <i>Drug Development Research</i> , 47:178-188 (1999).

EXAMINER

DATE CONSIDERED

9/13/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(R v. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

Serial No.

MBHB00-618-A

09/648,775

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

Applicant:

Biaggioni et al.

Filing Date:

8/22/00

Group:



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

M		Erickson, et al., "1,3,8-Trisubstituted Xanthines. Effects of Substitution Pattern upon Adenosine Receptor A ₁ /A ₂ Affinity", <i>J. Med. Chem.</i> , 34:1431-1435 (1991).
M		Buckle, et al., "Inhibition of Cyclic Nucleotide Phosphodiesterase by Derivatives of 1,3-Bis(cyclopropylmethyl)xanthine", <i>J. Med. Chem.</i> , 37:476-485 (1994).
M		Dalpiaz, et al., "De Novo Analysis of Receptor Binding Affinity Data of Xanthine Adenosine Receptor Antagonists", <i>Arzneim-Forsch/Drug Res.</i> , 230-233 (1995).
M		Bruns, "Adenosine Antagonism by Purines, Pteridines and Benzopteridines in Human Fibroblasts", <i>Biochemical Pharmacology</i> , 30:325-333 (1981).
M		Birdsall, et al., "Purine N-Oxides-XL The 3-Acyloxypurine 8-Substitution Reaction: Scope: Syntheses of 8-Substituted Xanthines and Guanines", <i>Tetrahedron</i> , 27:5969-5978 (1971).
M		Bergmann, et al., "Oxidation of Hypoxanthines, Bearing 8-Aryl or 8-Pyridyl Substituent, by Bovine Milk Xanthine Oxidase", <i>Biochimica et Biophysica Acta</i> , 275-289 (1977).
M		Van der Wenden, et al., "Mapping the Xanthine C8-region of the adenosine A ₁ Receptor with Computer Graphics," <i>European Journal of Pharmacology-Molecular Pharmacology Section</i> , 206:315-323 (1991).
M		Shimada, et al., "8-Polycycloalkyl-1,3-dipropylxanthines as Potent and Selective Antagonists for A1-Adenosine Receptors", <i>J. Med. Chem.</i> , 35:924-930 (1992).
M	Shimada, Borth	Borth, et al., "8-Dicyclopropylmethyl-1,3-dipropylxanthine: A Potent and Selective Adenosine A1 Antagonist with Renal Protective and Diuretic Activities", <i>J. Med. Chem.</i> , 34:466-469.
M		Mosselhi, et al., "Reactions of some 8-diazoxanthine derivatives", <i>Indian Journal of Chemistry</i> , 33B:236-242 (1994).

EXAMINER

DATE CONSIDERED

9/13/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

Serial No.

MBHB00-618-A

09/648,775

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)



RECEIVED

Baggioni et al.

FEB 22 2001

TECH CENTER 1600/2900

Filing Date:

8/22/00

Group:

1623

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
W	WO 92/12260	7/8/92	WIPO				
W	WO 93/23401	11/25/93	WIPO				
W	WO 92/00297	7/8/92	WIPO				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

EXAMINER

DATE CONSIDERED

9/13/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.